Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cancer and other diseases
3.2.1.2 Increasing government grants and support for development of cell and gene therapies
3.2.1.3 Increasing pharmaceutical R&D spending
3.2.2 Industry pitfalls & challenges
3.2.2.1 High risk of mutagenesis
3.2.2.2 Lack of standardized production systems for cell and gene therapy products
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Canada
3.4.3 Europe
3.5 Technology landscape
3.6 Pipeline analysis
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.1.1 Thermo Fisher Scientific Inc.
4.1.2 Boehringer Ingelheim International GmbH
4.1.3 Merck KGaA
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Company matrix analysis
4.5 Vendor matrix analysis
4.6 Competitive positioning matrix
4.7 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Cell therapy
5.2.1 Allogenic
5.2.1.1 Mesenchymal stem cells
5.2.1.2 T-cells
5.2.1.3 Natural killer cells
5.2.1.4 Hematopoietic stem cells
5.2.1.5 Other allogeneic cells
5.2.2 Autologous
5.2.2.1 Mesenchymal stem cells
5.2.2.2 T-cells
5.2.2.3 Natural killer cells
5.2.2.4 Hematopoietic stem cells
5.2.2.5 Other allogeneic cells
5.3 Gene therapy
5.3.1 Viral vectors
5.3.2 Non-viral vectors
Chapter 6 Market Estimates and Forecast, By Mode, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Contract manufacturing
6.3 In-house manufacturing
Chapter 7 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Oncology diseases
7.3 Cardiovascular diseases
7.4 Orthopedic diseases
7.5 Infectious diseases
7.6 Ophthalmology diseases
7.7 Other indications
Chapter 8 Market Estimates and Forecast, By End user, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Biopharmaceutical companies
8.3 Academic research institutes
8.4 Hospitals
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Boehringer Ingelheim International GmbH
10.2 Bluebird Bio, Inc.
10.3 Catalent, Inc.
10.4 Charles River Laboratories International, Inc.
10.5 Merck KGaA
10.6 Miltenyi Bioindustry (Miltenyi Biotec)
10.7 Samsung Biologics
10.8 Takara Bio Inc.
10.9 Thermo Fisher Scientific Inc
10.10 WuXi AppTec Co., Ltd.
